Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OpGen Inc OPGN

Healthcare Biotechnology
OpGen, Inc. is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company distributes molecular microbiology solutions that help guide clinicians with more information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The Company's... see more

Recent & Breaking News (OTCPK:OPGN)

OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q

GlobeNewswire May 24, 2024

OpGen Announced 1-for-10 Reverse Stock Split

GlobeNewswire May 16, 2024

OpGen Provides Update on Business Operations and Strategic Opportunities

GlobeNewswire April 29, 2024

OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K

GlobeNewswire April 23, 2024

OpGen Announces Acquisition of Preferred Stock by David Lazar

GlobeNewswire March 25, 2024

OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 14, 2023

OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds

GlobeNewswire October 12, 2023

OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 10, 2023

OpGen's Subsidiary Ares Genetics Releases New Features to its AREScloud Offering

GlobeNewswire August 7, 2023

OpGen's Subsidiary Curetis and FIND Extend R&D Collaboration Agreement

GlobeNewswire August 3, 2023

OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time

GlobeNewswire August 3, 2023

OpGen's Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND

GlobeNewswire July 19, 2023

OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe

GlobeNewswire June 26, 2023

OpGen's Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments

GlobeNewswire June 22, 2023

OpGen Presents Unyvero Urinary Tract Infection Panel Trial Results at ASM Microbe 2023 Conference

GlobeNewswire June 20, 2023

OpGen Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 15, 2023

OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time

GlobeNewswire May 8, 2023

OpGen Announces Closing of $3.5 Million Public Offering

GlobeNewswire May 4, 2023

OpGen Announces Pricing of $3.5 Million Public Offering

GlobeNewswire May 1, 2023

OpGen's Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND

GlobeNewswire April 26, 2023